This version (2025/01/14 14:45) was approved by manos.papadopoulos.The Previously approved version (2021/03/02 10:07) is available.This is an old revision of the document!
Table of Contents
Northern Lincolnshire and Goole NHS Foundation Trust - Nuclear Medicine
When this document is not viewed in the Nuclear Medicine Wiki, the reader is responsible for checking that it is the most current version. This can be checked at nlag.heynm.org.uk
| SOP Code | Title | Review Date |
|---|---|---|
| REF022 | Thyroid Metastases Imaging (I123 Whole Body Scan) | 2028-01-16 |
| Authorised By | Authorising Role | Authorisation Signature (only on master paper copy) | Date Authorised |
|---|---|---|---|
| Prof G Avery | ARSAC Licence Holder | 2025-01-14 |
REF022 - I123 Whole Body Imaging
See REF000 - Referring to Nuclear Medicine (NLAG) for details on how to refer.
Description
The main function of the thyroid gland is to concentrate and organify inorganic iodine, to store the iodinated compounds and then release them as active hormones into the circulation. Iodine-123 is an iodine radiopharmaceutical appropriate for thyroid imaging. Iodine-123 is therefore also able to determine the presence and extent of residual functioning thyroid tissue shortly post-thyroidectomy and, after I-131 ablation, to detect the presence and location of functioning thyroid cancer, recurrences and/or metastases. It can also be used for looking for sites of ectopic thyroid tissue outside of the neck/upper thorax.
| ARSAC Licence Holders |
|---|
| Prof Ged Avery |
| Dr Najeeb Ahmed |
| Nuclide | Pharmaceutical Form | Local DRL (MBq) |
|---|---|---|
| I123 | Sodium Iodide | 400 |
| Typical Radiation Dose (mSv) | 3.9 (for 200MBq) |
|---|
Staff Entitled to Refer
- The referrer may be any UK registered medical practitioner currently employed in Secondary Care.
- Referrals from Primary Care will be accepted if the investigation has been suggested by a a Secondary Care Specialist or a Consultant Radiologist in a report from a previous investigation; or following discussion with a Consultant Radiologist. Details of such suggestions or discussions should be included on the request form.
Supplementary Drugs
- Sodium chloride for parenteral use (0.9% w/v).
Contraindications
Patient Preparation
- Leave at least 8 weeks between administration of iodinated contrast media (as used in CT and X-ray procedures) and administration of the I-123[2]
- Avoid iodine medications containing iodine (e.g. antiseptics, eye drops, iodinated multivitamins or mineral supplements) for a minimum of 4 weeks[4],
- TSH should be elevated to greater than 30mIU/l. This can be achieved by withdrawing T4 for four weeks prior to imaging, with T3 replacement for two weeks and no hormone replacement for a further two weeks; or by administration of thyrogen on the two days before the administration of the I-123. [1] [2].
- The referrer must advise whether to use hormone withdrawal or thyrogen stimulation.
- Amiodarone can affect the uptake of radioiodines. If the patient is taking Amiodarone, this must be discussed with the ARSAC licence holder prior to administration. Note that amiodarone may have to be withdrawn:
- for 12 months to ensure optimal conditions for I-131 ablation therapy.
- for 3-6 months prior to imaging for ectopic thyroid tissue.
Clinical Indication(s)
| To determine the presence and extent of residual functioning thyroid tissue and the presence and location of functioning thyroid cancer (post thyroidectomy) |
| To localise sites of ectopic thyroid tissue outside of the neck/upper thorax |
